Straits Times Index
3,320.15 -1.93 (-0.06%) Nikkei
39,227.04 +188.88 (+0.48%) Hang Seng
18,366.95 0.00 (0.00%) FTSE 100
8,228.48 -16.89 (-0.20%) Bitcoin USD
69,410.73 -154.99 (-0.22%) CMC Crypto 200
1,440.11 -6.56 (-0.45%)
HROW Oct 2024 7.000 put
| Previous close | 1.6700 |
| Open | N/A |
| Bid | 0.1000 |
| Ask | 1.1500 |
| Strike | 7.00 |
| Expiry date | 2024-10-18 |
| Day's range | 1.6700 - 1.6700 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
Business WireMelt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
NASHVILLE, Tenn., June 06, 2024--Melt Pharmaceuticals, Inc. ("Melt"), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced that the first patient has been dosed in its Phase 3 program evaluating the safety and efficacy of its lead product candidate, MELT-300, a non‑IV, non-opioid tablet that combines fixed doses of midazolam (3mg) and ketamine (50mg). MELT-300 is administered sublingually using Catalent Inc.’s proprietary fast‑dissolving Zy
Business WireHarrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
NASHVILLE, Tenn., June 05, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is pleased to announce results from its ESSENCE‑2 open-label extension (OLE) clinical study for VEVYE® (cyclosporine ophthalmic solution) 0.1%, the first and only cyclosporine to treat the signs and symptoms of dry eye disease (DED). ESSENCE-2 OLE was a Phase 3, prospective, multicenter, open-label, clinical study with 202 patients, who had previously completed the ESSENCE‑2 study, re
Business WireHarrow to Present at Two Investor Conferences in May
NASHVILLE, Tenn., May 15, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor conferences in May:
